The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
ALS patients experience neuroinflammation and rapid neurodegeneration
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Subscribe To Our Newsletter & Stay Updated
